

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT TRANSMITTAL FORM


GP1623

#2
MW

Applicant(s): Wu et al.

Serial No. 10/023,604

For: SAPONIN DERIVATIVES USEFUL FOR INHIBITING
SIALYLTRANSFERASE AND BIOSYNTHESIS OF
SIALOGLYCOCONJUGATE



Filed: December 17, 2001

Examiner: Not Yet Assigned

Art Unit: Not yet assigned

Attorney Docket: 179.7294USU

COMMISSIONER FOR PATENTS
Washington, D.C. 20231

RECEIVED
FEB 25 2002
TECH CENTER 1600/2900

Sir:

Transmitted herewith is:

1. Information Disclosure Statement;
2. PTO Form 1449 with copies of patents;
3. Transmittal letter in duplicate; and
4. Postcard.

Please charge any additional fees or credit any such fees, if necessary to Deposit Account No. 01-0467 in the name of Ohlandt, Greeley, Ruggiero & Perle. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: February 11 2002

Paul D. Greeley, Esq.
Reg. No. 31,019
Ohlandt, Greeley, Ruggiero & Perle, L.L.P.
One Landmark Square, 10th Floor
Stamford, Connecticut 06901-2682
(203) 327-4500

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON February 11, 2002.

Kenroy Browne
NAME

SIGNATURE

02/11/02
DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Wu et al.

Serial No. 10/023,604

For: SAPONIN DERIVATIVES USEFUL FOR INHIBITING
SIALYLTRANSFERASE AND BIOSYNTHESIS OF
SIALOGLYCOCONJUGATE

Filed: December 17, 2001

Examiner: Not Yet Assigned

Art Unit: Not yet assigned

Attorney Docket: 179.7294USU

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

FEB 25 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with applicant's duty of disclosure under 37 C.F.R. §1.56, please find attached hereto form PTO-1449 listing information which may be material to the patentability of this application, filed concurrently herewith. This Information Disclosure Statement is being filed:

XXX Within three (3) months of the filing date of the national application;


___ Within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application;

___ Before the mailing date of a first Office Action on the merits;

___ After the filing date or date of first Office Action, but before the mailing date of a final action under 37 C.F.R. §1.113, provided that this occurs prior to the issuance of a Notice of Allowance and provided that this I.D.S. is accompanied by either a certification as specified in 37 C.F.R. §1.97(e) or the fee set forth in 37 C.F.R. §1.17(p);

___ After the filing date or date of first Office Action, but before the mailing date of a Notice of Allowance under 37 C.F.R. §1.311, provided that this occurs prior to the final action and provided that this I.D.S. is accompanied by either a certification as specified in 37 C.F.R. §1.97(e) or the fee set forth in 37 C.F.R. §1.17(p);

___ After the mailing date of a final action under 37 C.F.R. §1.113, provided that this occurs prior to the issuance of a Notice of Allowance and provided that this I.D.S. is accompanied by either a



certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of the I.D.S., and the petition fee set forth in 37 C.F.R. §1.17(i)(1); and

After the mailing date of a Notice of Allowance under 37 C.F.R. §1.311, provided that this occurs prior to the issuance of a final action and provided that this I.D.S. is accompanied by either a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of the I.D.S., and the petition fee set forth in 37 C.F.R. §1.17(i)(1).

RECEIVED

FEB 25 2002

Enclosed are copies of U.S. Patent Nos. 5,591,836 and 5,968,516.

Copies of the following articles are also enclosed herewith: *Planta Medica* 64

TECH CENTER 1600/2900

(1998) P. 5-7; *Glycoconjugate Journal* (1997) 14: 57-66; *Angew. Chem. Int. Ed.*

1999, 38, No. 10, 99.1379-1380; *Saponins Used in Traditional and Modern*

Medicine, Ed. Waller and Yamasaki, Plenum Press, New York, 1996; *The*

Journal of Cell Biology, 1997, Vol. 137, No. 6, pp. 1229-1241; *Glycobiology*,

1999, Vol. 9, No. 6, pp. 557-569; *Glycobiology*, 1993, Vol. 3, No. 3, pp. 201-217;

and *Proc. Nat. Acad. Sci. USA*, Vol. 69, No. 7, pp. 1838-1842.

It should be understood that attention has been called to the references that have been deemed to be pertinent to the claimed present invention. In concluding what was pertinent, the criteria employed was considered most appropriate in light of the invention shown in the present application. However, the Examiner or others may deem some other criteria to be just as appropriate or more appropriate. Therefore, the Examiner is respectfully urged to review the listed references and to make the usual careful independent search for other prior art that may be pertinent.

Respectfully submitted,

February 11, 2002

Paul D. Greeley
Reg. No. 31,019
Ohlandt, Greeley, Ruggiero & Perle, L.L.P.
One Landmark Square, 10th Floor
Stamford, CT 06901-2682
(203) 327-4500